2017
Primary cutaneous aggressive epidermotropic cytotoxic CD8+ T‐cell lymphoma: long‐term remission after brentuximab vedotin
Cyrenne BM, Subtil A, Girardi M, Foss F. Primary cutaneous aggressive epidermotropic cytotoxic CD8+ T‐cell lymphoma: long‐term remission after brentuximab vedotin. International Journal Of Dermatology 2017, 56: 1448-1450. PMID: 29047111, DOI: 10.1111/ijd.13792.Peer-Reviewed Original Research
2015
Resimmune, an anti-CD3ε recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma
Frankel AE, Woo JH, Ahn C, Foss FM, Duvic M, Neville PH, Neville DM. Resimmune, an anti-CD3ε recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma. Haematologica 2015, 100: 794-800. PMID: 25795722, PMCID: PMC4450625, DOI: 10.3324/haematol.2015.123711.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaT-cell lymphomaComplete remissionRecombinant immunotoxinCommon adverse eventsDose-escalation trialLow tumor burdenAssessment Tool scoreDurable remissionsEscalation trialPartial remissionAdverse eventsTumor burdenIntravenous infusionPatientsRemissionTool scoreResponse rateSingle-chain antibody fragmentChain antibody fragmentsLymphomaDiphtheria toxinFurther studiesImmunotoxinTrials
2006
Efficacy of low dose clofarabine in refractory precursor T- acute lymphoblastic leukemia.
Choi J, Foss F. Efficacy of low dose clofarabine in refractory precursor T- acute lymphoblastic leukemia. The Yale Journal Of Biology And Medicine 2006, 79: 169-72. PMID: 17940627, PMCID: PMC1994805.Peer-Reviewed Original ResearchMeSH KeywordsAdenine NucleotidesAdultArabinonucleosidesBone Marrow NeoplasmsClinical Trials as TopicClofarabineDrug Administration ScheduleDrug Resistance, NeoplasmHumansImmunophenotypingLeukemia-Lymphoma, Adult T-CellMaleRecurrenceSkin NeoplasmsStem Cell TransplantationTransplantation, HomologousTreatment OutcomeConceptsLow dose clofarabineLymphoblastic leukemiaAllogeneic stem cell transplantationSignificant clinical activityStem cell transplantationNear complete responseAcute lymphoblastic leukemiaPediatric B-ALLT-cell leukemiaAllogeneic transplantsComplete responsePoor prognosisCell transplantationB-ALLPrecursor TClinical activityNew agentsNovel nucleoside analogueClofarabinePatientsLeukemiaNucleoside analoguesSignificant activityRemissionTransplantation